Novartis Ag (NVS) Times Interest Earned (2009 - 2026)
Novartis Ag (NVS) posted Times Interest Earned of $10.28 for Q2 2026, down 38.91% sequentially from $16.83 in Q2 2025, and down 38.91% YoY from $16.83 in Q2 2025.
Novartis Ag (NVS) Times Interest Earned (2009 - 2026) Analysis & Trends
Novartis Ag has reported Times Interest Earned for 18 years, with the latest figure at $10.28 in Q2 2026.
- Quarterly Times Interest Earned fell 38.91% year-over-year to $10.28 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$90.67 (down 102.3% YoY) and the FY2025 annual result came in at $15.42, up 6.68% from the prior year.
- Times Interest Earned fell to $10.28 in Q2 2026 per NVS's latest filing, from $16.83 in the prior quarter.
- Over five years, Times Interest Earned peaked at $16.83 in Q2 2025 and troughed at -$169157.8 in Q1 2022.
- A 5-year average of -$17659.2 and a median of -$11.03 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned surged 213.61% in 2023, then tumbled 373.66% in 2024.
- Over 5 years, Times Interest Earned stood at -$50.93 in 2022, then jumped by 83.31% to -$8.5 in 2023, then sank by 373.66% to -$40.28 in 2024, then soared by 141.79% to $16.83 in 2025, then slumped by 38.91% to $10.28 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $10.28, $16.83, and -$40.28 for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2.64 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -50.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.28 |
| Jun 30, 2025 | 16.83 |
| Dec 31, 2024 | -40.28 |
| Jun 30, 2024 | -15.74 |
| Dec 31, 2023 | -8.50 |
| Jun 30, 2023 | 12.53 |
| Mar 31, 2023 | -25,003.81 |
| Dec 31, 2022 | -50.93 |
| Sep 30, 2022 | -3.27 |
| Jun 30, 2022 | -11.03 |
| Mar 31, 2022 | -169,157.82 |
| Dec 31, 2021 | -29.90 |
| Sep 30, 2021 | -3.59 |
| Jun 30, 2021 | -17.31 |
| Mar 31, 2021 | -69,310.48 |
| Dec 31, 2020 | -24.80 |
| Sep 30, 2020 | -86,127.77 |
| Jun 30, 2020 | -10.36 |
| Mar 31, 2020 | 0.19 |
| Jun 30, 2019 | -11.14 |